## Daniele Suzete Persike

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6472344/publications.pdf

Version: 2024-02-01

932766 887659 19 416 10 17 citations g-index h-index papers 19 19 19 831 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Adenosine A1 Receptor Agonist (R-PIA) before Pilocarpine Modulates Pro- and Anti-Apoptotic Factors in an Animal Model of Epilepsy. Pharmaceuticals, 2021, 14, 376.	1.7	1
2	Serendipitous discovery of phenylketonuria in Iraq $\hat{a} \in \text{``How to identify and treat?. Molecular Genetics}$ and Metabolism Reports, 2021, 27, 100737.	0.4	0
3	Challenges of post-traumatic stress disorder (PTSD) in Iraq: biochemical network and methodologies. A brief review. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	2
4	Long-Term Saccharin Consumption and Increased Risk of Obesity, Diabetes, Hepatic Dysfunction, and Renal Impairment in Rats. Medicina (Lithuania), 2019, 55, 681.	0.8	26
5	Altered Proteins in the Hippocampus of Patients with Mesial Temporal Lobe Epilepsy. Pharmaceuticals, 2018, 11, 95.	1.7	29
6	Hippocampal Proteome of Rats Subjected to the Li-Pilocarpine Epilepsy Model and the Effect of Carisbamate Treatment. Pharmaceuticals, 2017, 10, 67.	1.7	11
7	Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Behavioural Brain Research, 2014, 274, 390-399.	1.2	75
8	Reduced hippocampal manganese-enhanced MRI (MEMRI) signal during pilocarpine-induced status epilepticus: Edema or apoptosis?. Epilepsy Research, 2014, 108, 644-652.	0.8	20
9	Proteomics-Based Strategy to Identify Biomarkers and Pharmacological Targets in Temporal Lobe Epilepsy. , 2013, , 115-126.		1
10	Hippocampal proteomic profile in temporal lobe epilepsy. Journal of Epilepsy and Clinical Neurophysiology, 2012, 18, 53-56.	0.1	19
11	Consequences of pilocarpine-induced status epilepticus in immunodeficient mice. Brain Research, 2012, 1450, 125-137.	1.1	4
12	Neuroprotective effect of pyruvate and oxaloacetate during pilocarpine induced status epilepticus in rats. Neurochemistry International, 2011, 58, 385-390.	1.9	30
13	Differential neuroprotection by A1 receptor activation and A2A receptor inhibition following pilocarpine-induced status epilepticus. Epilepsy and Behavior, 2011, 22, 207-213.	0.9	30
14	The A1 receptor agonist R-Pia reduces the imbalance between cerebral glucose metabolism and blood flow during status epilepticus: Could this mechanism be involved with neuroprotection?. Neurobiology of Disease, 2011, 41, 169-176.	2.1	9
15	Adenosina e neuroproteção na epilepsia do lobo temporal: da ativação do receptor A1 ao bloqueio do receptor A2A. Journal of Epilepsy and Clinical Neurophysiology, 2010, 16, 64-67.	0.1	1
16	Acute and chronic exercise modulates the expression of MOR opioid receptors in the hippocampal formation of rats. Brain Research Bulletin, 2010, 83, 278-283.	1.4	48
17	Alteration of purinergic P2X4 and P2X7 receptor expression in rats with temporal-lobe epilepsy induced by pilocarpine. Epilepsy Research, 2009, 83, 157-167.	0.8	74
18	Protective effect of the organotelluroxetane RF-07 in pilocarpine-induced status epilepticus. Neurobiology of Disease, 2008, 31, 120-126.	2.1	35

#	Article	IF	CITATIONS
19	Epilepsia e neuroproteção: o papel do agonista adenosinérgico A1(RPia) na modulação da crise induzida por pilocarpina. Journal of Epilepsy and Clinical Neurophysiology, 2008, 14, 106-110.	0.1	1